Niacin/lovastatin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
No edit summary
Line 1: Line 1:
{{Drugbox
| type              = combo
| image            = Niacinstr.png
| image2            = Lovastatin.png
| component1        = Niacin
| class1            = n/a
| component2        = Lovastatin
| class2            = [[Statin]]
| CAS_number        =
| ATC_prefix        = C10
| ATC_suffix        = BA01
| PubChem          =
| DrugBank          =
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  X
| pregnancy_category= 
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US          =  Rx-only
| legal_status      =
| routes_of_administration = Oral
}}
{{CMG}}
__NOTOC__
__NOTOC__
{{Niacin/lovastatin}}
{{CMG}}; {{AE}} {{SS}}


'''''For patient information about Niacin/lovastatin, click [[Niacin/lovastatin (patient information)|here]].'''''
{{SB}} ADVICOR<sup>®</sup>


==Overview==
==Overview==


'''Niacin/lovastatin''' (tradename Advicor) is a drug combination used for the treatment of [[dyslipidemia]]. It is a combination of [[niacin]] and the [[statin]] drug [[lovastatin]] (best known as '''Mevacor''' in the U.S.). The combination preparation is marketed by [[Abbott Laboratories]]
'''Niacin/lovastatin''' (trade names '''Advicor''', '''Mevacor''') is a drug combination used for the treatment of [[dyslipidemia]]. It is a combination of the vitamin [[niacin]] and the [[statin]] drug [[lovastatin]]. The combination preparation is marketed by [[Abbott Laboratories]]


It was approved by the FDA on December 17, 2001.
It was approved by the FDA on December 17, 2001.
==Category==
Combination drugs;Hypolipidemic agents;Cardiovascular Drugs;
==FDA Package Insert==
'''  [[Niacin/lovastatin indications and usage|Indications and Usage]]'''
'''| [[Niacin/lovastatin dosage and administration|Dosage and Administration]]'''
'''| [[Niacin/lovastatin dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Niacin/lovastatin contraindications|Contraindications]]'''
'''| [[Niacin/lovastatin warnings and precautions|Warnings and Precautions]]'''
'''| [[Niacin/lovastatin adverse reactions|Adverse Reactions]]'''
'''| [[Niacin/lovastatin drug interactions|Drug Interactions]]'''
'''| [[Niacin/lovastatin use in specific populations|Use in Specific Populations]]'''
'''| [[Niacin/lovastatin overdosage|Overdosage]]'''
'''| [[Niacin/lovastatin description|Description]]'''
'''| [[Niacin/lovastatin clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Niacin/lovastatin nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Niacin/lovastatin clinical studies|Clinical Studies]]'''
'''| [[Niacin/lovastatin how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Niacin/lovastatin patient counseling information|Patient Counseling Information]]'''
'''| [[Niacin/lovastatin labels and packages|Labels and Packages]]'''
==Mechanism of Action==


==Dosage==
===Niacin===
The combination is available as tablets containing:.<ref>{{cite web |url=http://www.rxlist.com/cgi/generic/advicor_ids.htm |title=Advicor package insert, How Supplied section |accessdate=2008-03-15 |format= |work= }}</ref>
* 500 mg/20 mg
* 750 mg/20 mg
* 1000 mg/20 mg
* 1000 mg/40 mg


==External links==
The mechanism by which niacin alters lipid profiles is not completely understood and may involve several actions, including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity (which may increase the rate of chylomicron triglyceride removal from plasma). Niacin decreases the rate of hepatic synthesis of VLDL-C and LDL-C, and does not appear to affect fecal excretion of fats, sterols, or bile acids.
* [http://www.advicor.com Advicor] website
 
===Lovastatin===
 
Lovastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate. The conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol. Lovastatin is a prodrug and has little, if any, activity until hydrolyzed to its active beta-hydroxyacid form, lovastatin acid. The mechanism of the LDL-lowering effect of lovastatin may involve both reduction of VLDL-C concentration and induction of the LDL receptor, leading to reduced production and/or increased catabolism of LDL-C.
 
==Interaction with Alcohol==
 
ADVICOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease.Patients should be advised to '''avoid'''  ingestion of alcohol, hot beverages and spicy foods around the time of ADVICOR administration.
==References==
 
{{Reflist|2}}


{{Statins}}
{{Statins}}
{{DEFAULTSORT:Niacin lovastatin}}
[[Category:Hypolipidemic agents]]
[[Category:Combination drugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drugs]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 21:22, 18 February 2014

Niacin/lovastatin
ADVICOR® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Niacin/lovastatin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Niacin/lovastatin, click here.

Synonyms / Brand Names: ADVICOR®

Overview

Niacin/lovastatin (trade names Advicor, Mevacor) is a drug combination used for the treatment of dyslipidemia. It is a combination of the vitamin niacin and the statin drug lovastatin. The combination preparation is marketed by Abbott Laboratories

It was approved by the FDA on December 17, 2001.

Category

Combination drugs;Hypolipidemic agents;Cardiovascular Drugs;

FDA Package Insert

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

Niacin

The mechanism by which niacin alters lipid profiles is not completely understood and may involve several actions, including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity (which may increase the rate of chylomicron triglyceride removal from plasma). Niacin decreases the rate of hepatic synthesis of VLDL-C and LDL-C, and does not appear to affect fecal excretion of fats, sterols, or bile acids.

Lovastatin

Lovastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate. The conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol. Lovastatin is a prodrug and has little, if any, activity until hydrolyzed to its active beta-hydroxyacid form, lovastatin acid. The mechanism of the LDL-lowering effect of lovastatin may involve both reduction of VLDL-C concentration and induction of the LDL receptor, leading to reduced production and/or increased catabolism of LDL-C.

Interaction with Alcohol

ADVICOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease.Patients should be advised to avoid ingestion of alcohol, hot beverages and spicy foods around the time of ADVICOR administration.

References

Template:Statins

Retrieved from "https://www.wikidoc.org/index.php?title=Niacin/lovastatin&oldid=944799"